HURA

PHARMACEUTICAL PREPARATIONS

TuHURA Biosciences, Inc. - Common Stock (HURA) [ST]

$2.18

▲ 0.46%

prev close

TuHURA Biosciences Inc is a phase 3 clinical stage immuno-oncology company with three distinct technologies focused on the development of novel therapeutics designed to overcome primary and acquired resistance to cancer immunotherapies. The company's personalized cancer vaccine candidate, IFx-2.0, is designed to overcome primary resistance to checkpoint inhibitors. The company operates in one reportable segment, which includes all activities related to advancing therapies for cancer treatment.

Congressional Trades

All tracked trades

Members Trading

Unique members

Net Activity

0 buys · 0 sells

Members Who Traded This Stock

1 trade events

Date	Member	Stock	Type	Amount	Filed	Signal
2024-10-18	RHLaurel Lee	HURATuHURA Biosciences, Inc. - Common Stock	Exchange	$100,001 - $250,000	559d ago	—

2024-10-18

Laurel Lee

HURA

Exchange

Amount

$100,001 - $250,000

Filed

559d ago

Recent News

Merkel Cell Carcinoma Market Set for Rapid Growth in the Coming 10 Years Across the 7MM | DelveInsight

GlobeNewswire Inc.·2025-08-20

TuHURA R&D Jumps 75% in Q2

The Motley Fool·2025-08-15

SHAREHOLDER INVESTIGATION: Halper Sadeh LLC Investigates SHYF, ML, HURA, KANT on Behalf of Shareholders

Benzinga·2024-12-19

SHAREHOLDER INVESTIGATION: Halper Sadeh LLC Investigates ML, PDCO, HURA, KANT on Behalf of Shareholders

GlobeNewswire Inc.·2024-12-14

SHAREHOLDER ALERT: The M&A Class Action Firm Investigates the Merger of Kineta, Inc. - KANT

Benzinga·2024-12-12

Trade Timeline

Congressional activity, newest first

Laurel Lee

2024-10-18 · Exchange

$100,001 - $250,000